Five Prime Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Five Prime Therapeutics Inc (FPRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Peer Data As of Q4 2020
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/FPRX/competitors
https://api.csimarket.com/api/v1/companies/FPRX/relationships
https://api.csimarket.com/api/v1/companies/FPRX/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Five Prime Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Five Prime Therapeutics Inc | - | No | No | No |
| High-Confidence Competitors (72) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
FPRX Stock Performance relative to its Competitors
FPRX
Competitors (weighted)
Percent change over the selected range
FPRX Stock Performance relative to High-Confidence Competitors
FPRX
High-Confidence Competitors (equal-weighted, 72)
Percent change over the selected range
Competitor data is not yet available for Five Prime Therapeutics Inc.
Five Prime Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Five Prime Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Briacell Therapeutics Corp | Company report | 85% |
| Zevra Therapeutics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| G1 Therapeutics Inc | Company report | 85% |
| Adlai Nortye Ltd | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Altimmune inc | Company report | 85% |
| ADAPTIN BIO, INC. | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Cardiff Oncology Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Camp4 Therapeutics Corporation | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Avastin | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| HUMIRA | Company report | 85% |
| Telomir Pharmaceuticals Inc | Company report | 85% |
| Shuttle Pharmaceuticals Holdings Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Sandoz Inc. | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Inmune Bio Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Jiayin Group Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Xencor Inc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Akebia Therapeutics Inc | Company report | 85% |
| Foghorn Therapeutics Inc | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Dermata Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Immunovant Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Alvotech | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Kodiak Sciences Inc | Company report | 85% |
| Eqrx Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Argenx Se | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Iteos Therapeutics Inc | Company report | 85% |
Competitor Evidence Detail
Company report basis, confidence, active dates and source counts for Five Prime Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.